Omnicell (NASDAQ:OMCL - Get Free Report) posted its earnings results on Thursday. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.42 by $0.16, Briefing.com reports. Omnicell had a return on equity of 5.66% and a net margin of 3.13%. During the same period last year, the company earned $0.51 earnings per share. The company's revenue was down .9% compared to the same quarter last year.
Here are the key takeaways from Omnicell's conference call:
- Third-quarter results exceeded guidance, with revenue of $308 million and non-GAAP EBITDA of $45 million, supported by favorable product mix, gross margins, disciplined spending, and cost efficiencies.
- Omnicell raised full-year 2026 non-GAAP EBITDA guidance to $187 million–$193 million and EPS guidance to $2.48–$2.56, while narrowing revenue and ARR ranges because of improved visibility.
- The company said the Titan XT and OmniSphere pipeline grew modestly and became more mature, with Titan XT shipments beginning shortly and OmniSphere general availability still targeted for the first half of 2027. Management views OmniSphere subscriptions as a potentially high-margin, incremental revenue stream over time.
- Product bookings remain heavily back-end weighted, and management cited the timing of medium and large health-system decisions, competitive deal outcomes, and lengthy implementation cycles as sources of quarter-to-quarter variability.
- Second-half memory and component costs are expected to reduce margins by roughly $6 million, with about half incurred in the third quarter and the remainder expected in the fourth quarter; policy changes surrounding the 340B program are also expected to have a modest impact on 2026 ARR.
Omnicell Stock Performance
Omnicell stock traded down $0.02 during mid-day trading on Thursday, reaching $35.93. The company's stock had a trading volume of 430,889 shares, compared to its average volume of 639,864. The business has a 50 day moving average price of $34.57 and a 200-day moving average price of $39.26. The company has a current ratio of 1.64, a quick ratio of 1.43 and a debt-to-equity ratio of 0.13. Omnicell has a twelve month low of $30.69 and a twelve month high of $55.00. The firm has a market cap of $1.63 billion, a price-to-earnings ratio of 43.04, a PEG ratio of 0.95 and a beta of 0.98.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on OMCL shares. Zacks Research raised shares of Omnicell from a "strong sell" rating to a "hold" rating in a research report on Monday, September 7th. Piper Sandler restated an "overweight" rating and issued a $45.00 price target (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. Wells Fargo & Company cut their price target on shares of Omnicell from $55.00 to $50.00 and set an "overweight" rating on the stock in a report on Friday, July 31st. KeyCorp reiterated an "overweight" rating on shares of Omnicell in a research note on Monday, August 24th. Finally, Weiss Ratings raised shares of Omnicell from a "hold (c-)" rating to a "hold (c)" rating in a report on Tuesday, August 18th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $57.86.
Check Out Our Latest Analysis on Omnicell
About Omnicell
(
Get Free Report)
Omnicell, Inc develops medication management and adherence solutions for health care providers, pharmacies and patients. Its technologies are designed to help automate medication dispensing, improve inventory control, support clinical workflows and enhance medication access and adherence across the care continuum.
The company's product portfolio includes automated dispensing cabinets for hospitals and health systems, central pharmacy and intravenous compounding automation, medication packaging and adherence solutions, and software for analytics, inventory management and pharmacy operations.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.